Mumbai Borivali
| Sl.No | Principal Investigator’s Name | Study Title | Phase | Protocol Number | Indications | Department | Study Status | Link | Contact Person & Contact Details |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Dr Indoo Ammbulkar | A Randomized, Open-Label, Phase 3 Study of LY3484356 vs Investigator’s Choice of Endocrine Therapy, in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy | Phase 3 | LY2835219 | Breast Cancer | Department of Medical Oncology | Ongoing | NA | Anu Koundal – 9899844877 |
| 2 | Dr Indoo Ammbulkar | A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN) | Phase 3 | D910SC00001 | Esophageal Squamous Cell Carcinoma | Department of Medical Oncology | Initial stage | https://clinicaltrials.gov/ct2/show/NCT04550260 | Shilpa Daniel – 9953233963 |
| 3 | Dr Indoo Ammbulkar | A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) | Phase 3 | D967RC00001 | Breast Cancer | Department of Medical Oncology | Initial stage | https://clinicaltrials.gov/ct2/show/NCT05113251 | Ankita Solanki – 9820225226 |
